News

SAGA expands with two diagnostics scientists to further accelerate launch of new products and services

LUND, Sweden — /March 30, 2020/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces the appointment of two new team members to significantly strengthen SAGA’s R&D team: Sofia Birkeälv, PhD as Molecular Diagnostics Scientist, NGS Lead,…

SAGA Diagnostics extends its collaboration with Servier to use ultrasensitive SAGAsafe® technology in cancer clinical trials

LUND, Sweden – /January 28, 2020/ – SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces it has entered service agreements with the international pharmaceutical company Servier, based in Paris, France. These deals exemplify the…

SAGA seeks sales executive Germany and sales executive Spain

2 POSITIONS: Sales Executive, Germany and Sales Executive, Spain SAGA Diagnostics AB is seeking a talented and highly motivated staff with strong interest in bringing a new technology to the market and thus advancing our mission to revolutionize cancer diagnostics through proprietary ultrasensitive technologies that measure circulating tumor DNA in…

Now recruiting 2 job positions: Senior Molecular Diagnostics Scientist NGS + Molecular Diagnostics Scientist dPCR

[*** BOTH POSITIONS FILLED ***] POSITION 1: Senior Molecular Diagnostics Scientist, NGS SAGA Diagnostics AB is seeking a talented and highly motivated NGS scientist with strong interest in advancing our mission to revolutionize cancer diagnostics through proprietary ultrasensitive technologies that measure circulating tumor DNA in minimally-invasive “liquid biopsies” such as…

SAGA expands with four new team members to further accelerate commercial and medical development

LUND, Sweden — /November 7, 2019/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces the appointment of four people to significantly strengthen SAGA’s team: Annina Hube, PhD MBA, as Director of Market Access, Rocco Crescenzo, MD as Chief…

SAGA lands agreement with Region Örebro University Hospital to deploy ultrasensitive liquid biopsy testing in lung cancer

LUND, Sweden — /September 9, 2019/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces it has entered a “lab-in-lab” customer agreement with the University Hospital Örebro (USÖ), Division of Laboratory Medicine, serving the…

Appointment of Director of Operations

LUND, Sweden — /September 2, 2019/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces the appointment of a new Director of Operations, Johanna Asklin, PhD, an experienced professional project and portfolio manager in the…

SAGA raises 40 million SEK (€3.7 million) to advance ultrasensitive cancer liquid biopsies

LUND, Sweden and OSLO, Norway, June 11, 2019 — /B3C Newswire/ — SAGA Diagnostics AB, a precision oncology genomics testing company focused on ultrasensitive monitoring of cancer patients using blood samples and other liquid biopsies and tissues, today announces the raising of SEK 40 million in venture-backed financing (circa EUR…

SAGA appoints new Director of Finance

LUND, Sweden — /February 11, 2019/ — SAGA Diagnostics AB, a genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients using a simple blood sample, today announces the appointment of a new Director of Finance, Henrik Simonsen, a veteran strategic CFO with over 20 years…

Selected as Top 7 Start-Up Finalist in ‘Hello Tomorrow’ Global Heath Competition

LUND, Sweden — /January 10, 2019/ — SAGA Diagnostics announces today that we have been selected as a Worldwide Top 7 Finalist in the Global Health category, Hello Tomorrow Start-Up Competition!  Out of more than 4,500 companies from over 100 countries screened, we were selected by a prestigious industry panel…